QIMR Berghofer Medical Research Institute
The research program sought out to identify genes involved in maintaining the genome in the ‘correct’ epigenetic state. ACRF’s funding provided fit-out of equipment for the centre.
Epigenetics is the study of mechanisms which modify DNA structure, and thus change gene expression, without influencing the DNA base sequence. This program had a particular interest in the molecular mechanisms of epigenetic modification and how these mechanisms influence phenotype.
Such information has relevance to our ability to understand the genesis and development of cancer both for familial and sporadic cancer. In 2007, this was a new area of research.
This research program at QIMR was the first of its kind in the world and used the power of forward genetics to identify new genes involved in a range of human cancers.
Chief Investigators: Professor Emma Whitelaw, Professor Georgia Chenevix-Trench, Professor Nick Hayward
What your donations have achieved
Cervical cancer vaccine
We gave initial seed funding to Professor Ian Frazer’s research into the cervical cancer (HPV). Over 150 million doses of vaccine have been delivered worldwide to date.
The pill that melts away cancer
Our long term support of cancer research at WEHI has led to a treatment that melts away certain advanced forms of chronic lymphocytic leukaemia. It has been approved for clinical use in the US, European Union and Australia and is being trialled for other types of cancer.
Personalised cancer diagnosis
In 2015, we awarded $10 million seed funding to an ambitious cancer proteome project that aims to provide each cancer patient a personalised treatment plan within 36 hours. This will improve treatment outcomes and help avoid unnecessary treatments.
Zero childhood cancer
We are one of the founding partners of the initiative that will tackle the most serious cases of infant, childhood and adolescent cancer in Australia. It is a key step towards the program vision of one day helping to cure 100% of children with cancer.